# Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients

> **NCT00522548** · PHASE4 · TERMINATED · sponsor: **University of Pennsylvania** · enrollment: 37 (actual)

## Conditions studied

- Transplants and Implants

## Interventions

- **DRUG:** Enteric coated mycophenolate sodium
- **DRUG:** Mycophenolate mofetil

## Key facts

- **NCT ID:** NCT00522548
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-03
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 37 (ACTUAL)
- **Why stopped:** enrollment halted in order to have all patients complete follow-up by Jan 2011
- **Last updated:** 2018-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00522548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00522548, "Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00522548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*